Avience Biomedicals (NSE:AVIENCE) Total Long-Term Assets: ₹193.5 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
18 GF Score
Price ₹250.90
! 3 Warning Signs
View Full Analysis

What is Avience Biomedicals Total Long-Term Assets?

Avience Biomedicals NSE:AVIENCE +1.17% 18 Total Long-Term Assets is ₹193.5 Mil as of Mar. 2025. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Avience Biomedicals's Total Long-Term Assets for the quarter that ended in Mar. 2025 was ₹193.5 Mil.

Avience Biomedicals Total Long-Term Assets Related Terms

Avience Biomedicals Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals Total Long-Term Assets Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
Total Long-Term Assets
31.40 116.10 193.51

Avience Biomedicals Semi-Annual Data
Mar23 Mar24 Mar25
Total Long-Term Assets 31.40 116.10 193.51
NSE:AVIENCE
18GF Score
Avience Biomedicals Ltd NSE:AVIENCE
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of ₹193.5 Mil mean?
Avience Biomedicals (NSE:AVIENCE) has a Total Long-Term Assets of ₹193.5 Mil as of Mar. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Avience Biomedicals and its competitors.
Is Avience Biomedicals' Total Long-Term Assets too high?
Avience Biomedicals' current Total Long-Term Assets is ₹193.5 Mil. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Total Long-Term Assets compare to ABT and SYK?
Avience Biomedicals' Total Long-Term Assets of ₹193.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Avience Biomedicals and its competitors. Avience Biomedicals's current Total Long-Term Assets is ₹193.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Total Long-Term Assets of ₹193.5 Mil. The current Total Long-Term Assets is ₹193.5 Mil. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Total Long-Term Assets is ₹193.5 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score

Get the complete analysis for NSE:AVIENCE

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹250.90
Price